Physician profile
Tolulope Adeyemo
NPI 1841588068
$1,970.58
in general payments reported to CMS, 2019-2025
33 companies · $909 in 2025
The $909 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $229 · 2021: $76.66 · 2023: $13.25 · 2024: $51.76 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $974.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $351.60 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astellas Pharma US INC | $245.18 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $157.38 | 2019-2025 | Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $141.78 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.37 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $115.39 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $107.11 | 2019-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $74.35 | 2024-2025 | |
| Dynavax Technologies Corporation | $50.22 | 2025 | Heplisav-B |
| Merck Sharp & Dohme LLC | $47.99 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Abbott Laboratories | $44.07 | 2025 | Freestyle Libre 3 |
| Abbvie INC. | $43.32 | 2021-2025 | |
| Gilead Sciences, INC. | $37.83 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.04 | 2025 | Jardiance |
| Sumitomo Pharma America, INC. | $33.93 | 2025 | Gemtesa |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $30.18 | 2019-2020 | |
| Coloplast Corp | $29.02 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.95 | 2019-2025 | |
| Genentech USA, INC. | $27.70 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.47 | 2019-2020 | |
| Inspire Medical Systems, INC. | $26.94 | 2025 | Inspire |
| Allergan, INC. | $23.99 | 2019 | |
| Shield Therapeutics INC | $23.47 | 2025 | |
| Phadia US INC. | $18.12 | 2019 | |
| Horizon Therapeutics Plc | $17.55 | 2020 | |
| Ibsa Pharma INC. | $16.86 | 2020 | |
| Dermira, INC. | $16.21 | 2019 | |
| Exact Sciences Corporation | $16.11 | 2025 | Cologuard Collection Kit |
| Nalpropion Pharmaceuticals LLC | $14.18 | 2019 | |
| Eisai INC. | $13.84 | 2019 | |
| Pfizer INC. | $12.43 | 2019 | |
| Ironshore Pharmaceuticals INC. | $11.56 | 2019 | |
| Adlon Therapeutics L.P. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tolulope Adeyemo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.